BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Summit Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Summit Therapeutics's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05689853-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT05689853)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: Study of AK119 Combined With A
 K112 in Patients With Advanced Solid Tumors\nEstimated primary completion:
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivone
 scimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05689853
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767527-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06767527)
DESCRIPTION:Ivonescimab\, phase 3.\nStudy: AK112 or Placebo Plus Nab-Paclit
 axel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Tr
 iple-negative Breast Cancer\nEstimated primary completion: December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06767527
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06646055-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT06646055)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: AK112 and Cadonilimab Combined
  With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer\nEstim
 ated primary completion: 30 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06646055
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05227664-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT05227664)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Study of AK117/AK112 in Metast
 atic Triple-Negative Breast Cancer\nEstimated primary completion: 30 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT052
 27664
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05229497-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT05229497)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: A Phase Ib/II Study of AK112 i
 n Combination With AK117 in Advanced Malignant Tumors\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05229497
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06601335-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06601335)
DESCRIPTION:Ivonescimab\, phase 3.\nStudy: A Phase 3 Study of AK112 Plus AK
 117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous
  Cell Carcinoma (R/M HNSCC)\nEstimated primary completion: January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06601335
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951503-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270114
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06951503)
DESCRIPTION:Ivonescimab\, phase 3\, Metastatic Colorectal Cancer.\nStudy: A
 K112 and Chemotherapy in First-line Metastatic Colorectal Cancer\nEstimate
 d primary completion: 13 January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06951503
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07357220-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07357220)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: A Study of AK112 in Combinatio
 n With VG2025 in Colorectal Cancer With Liver Metastases\nEstimated primar
 y completion: 28 February 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07357220
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06938321-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT06938321)
DESCRIPTION:Ivonescimab\, phase 1/2\, Biliary Tract Cancer.\nStudy: A Study
  of AK130 in Combination With AK112 for the Treatment of Advanced Biliary 
 Tract Cancer\nEstimated primary completion: May 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06938321
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06928389-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06928389)
DESCRIPTION:Ivonescimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ivo
 nescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Can
 cer\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06928389
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052253-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07052253)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Phase II Clinical Study of AK1
 04/AK112 in Combination With TT-00420 Tablet for Advanced HCC.\nEstimated 
 primary completion: 10 May 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07052253
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953999-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270514
DTEND;VALUE=DATE:20270515
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06953999)
DESCRIPTION:Ivonescimab\, phase 3.\nStudy: A Phase III Study of Ivonescimab
  + Chemo With/Without AK117 in Metastatic Pancreatic Cancer\nEstimated pri
 mary completion: 14 May 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06953999
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07114315-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07114315)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Study of AK130 in Combination 
 With AK112 for the Treatment of Advanced Pancreatic Cancer\nEstimated prim
 ary completion: August 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07114315
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669779-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07669779)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small C
 ell Lung Cancer\nEstimated primary completion: 30 August 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07669779
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591090-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07591090)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Phase II Study of AK146D1 Comb
 ined With AK112 in Advanced Breast Cancer\nEstimated primary completion: 1
  September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivon
 escimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07591090
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686030-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06686030)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Combination Therapy of AK112 Wit
 h Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer\nEstim
 ated primary completion: October 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06686030
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07245446-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07245446)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Study of Ivonescimab in First-
 Line ES-SCLC\nEstimated primary completion: December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07245446
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767514-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06767514)
DESCRIPTION:Ivonescimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Cli
 nical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Pa
 tients With High PD-L1\nEstimated primary completion: April 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06767514
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228832-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT07228832)
DESCRIPTION:Ivonescimab\, phase 3\, Metastatic Colorectal Cancer.\nStudy: P
 hase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patie
 nts With Metastatic Colorectal Cancer\nEstimated primary completion: 31 Ma
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07228
 832
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560124-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07560124)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: A Study of AK138D1 Alone or in
  Combination With Ivonescimab in Advanced Breast Cancer\nEstimated primary
  completion: 6 June 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07560124
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623356-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280618
DTEND;VALUE=DATE:20280619
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07623356)
DESCRIPTION:Ivonescimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non
 -Small Cell Lung Cancer\nEstimated primary completion: 18 June 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07623356
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636772-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280824
DTEND;VALUE=DATE:20280825
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07636772)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Phase II Study of AK146D1 Mono
  or Combined With AK112 in Advanced Urothelial Carcinoma\nEstimated primar
 y completion: 24 August 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07636772
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07158840-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07158840)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: AK1
 12 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actiona
 ble Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase 
 Inhibitor (TKI) Treatment\nEstimated primary completion: September 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07158840
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05899608-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT05899608)
DESCRIPTION:Ivonescimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Cli
 nical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Pa
 tients\nEstimated primary completion: 31 December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05899608
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010263-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT07010263)
DESCRIPTION:Ivonescimab\, phase 3.\nStudy: A Study of AK112 as Consolidatio
 n Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Hav
 e Not Progressed Following Concurrent Chemoradiation Therapy\nEstimated pr
 imary completion: 31 December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07010263
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07877194-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20290412
DTEND;VALUE=DATE:20290413
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07877194)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Clinical Study of Ivonescimab 
 in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer\nE
 stimated primary completion: 12 April 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07877194
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07815665-2023@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Ivonescimab: Phase 2/3 readout est. (NCT07815665)
DESCRIPTION:Ivonescimab\, phase 2/3.\nStudy: A Study of Ivonescimab in Comb
 ination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfor
 tumab Vedotin in Metastatic Urothelial Carcinoma\nEstimated primary comple
 tion: 31 October 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07815665
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
